Last edition
News about
EMA Approves Dupixent as First-Ever Targeted Therapy for Patients with COPD
The European Medicines Agency (EMA) has recently announced their approval for Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.
Heron Therapeutics Announces Acceptance of the PAS Application for ZYNRELEF
Heron Therapeutics, Inc. has announced that the FDA acknowledged the receipt of the company's Prior Approval Supplement (PAS) application for ZYNRELEF (bupivacaine and meloxicam) extended-release solution VAN.
Aurigene and Edity to Partner in Cell Therapy
Aurigene Pharmaceutical Services Ltd. has announced that it will provide discovery services to Edity Therapeutics in cell therapy.
Tobin Scientific Announces Acquisition of BioRepository Resources
Tobin Scientific has acquired BioRepository Resources LLC (BRR), a leader in biological sample storage and management solutions, located in New Providence, New Jersey.
Techinvention Lifecare Joins BVI as Consultant for Veterinary Vaccine Manufacturing Facility
Techinvention Lifecare Pvt. Ltd. has announced its appointment as a consultant by Botswana Vaccine Institute (BVI) to monitor the setting up of the new state-of-the-art and cGMP-compliant, vaccine manufacturing unit in its existing facility at Gaborone, Botswana.
EMA Accepts Approval for AstraZeneca MAA for Sipavibart
AstraZeneca has announced that its Marketing Authorisation Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients.
Genezen to Acquire uniQure Commercial Gene Therapy Manufacturing Operations in Lexington
Genezen has inked an agreement to acquire uniQure's commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and a world-class team of employees to the company.
Anbogen Therapeutics Secures Additional USD 7.3 Million in A+ Round Financing
Anbogen Therapeutics, Inc. has received USD 7.3 million oversubscribed A+ round financing, which is a direct continuation of the USD 12.5 Million Series A on February 1, 2024, bringing the total raised to USD 19.8 million.
Alembic Pharma Secures USFDA Tentative Approval for Bosutinib Tablets
Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Bosutinib Tablets, 100 mg and 500 mg.
Avanos Medical Appoints Indrani Franchini to Board of Directors
Franchini served as Executive Vice President and Chief Legal Officer at Alnylam Pharmaceuticals. From June 2017 to July 2021, she served as Executive Vice President and Chief Compliance Officer at Alexion Pharmaceuticals, Inc., where she led a comprehensive transformation of the company's compliance program.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy